Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
Authors:
Open Access
- 2 July 2022
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 42, 42-49
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross‐sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) studyBJU International, 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implicationsAnnals of Oncology, 2012
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Using PSA to Guide Timing of Androgen Deprivation in Patients with T0–4 N0–2 M0 Prostate Cancer not Suitable for Local Curative Treatment (EORTC 30891)European Urology, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Quality of Life in Prostate Cancer Patients Taking Androgen Deprivation TherapyJournal of the American Geriatrics Society, 2005
- Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trialBJU International, 2002
- Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelinesBMJ, 1999
- Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluationsThe Lancet, 1993